|Related Categories||Abbott, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience,|
|Gene Information||human ... PPARA(5465)|
PPARα agonist; lipid regulating drug. Increases high density lipoprotein levels by reducing cholesteryl ester transfer protein expression.
Download BioFiles v7 n5 (3.18 Mb PDF) Back to Pharmaceutical Drugs and Drug Candidates homepage
BioFiles v7 n5, 2012, 21–24
Keywords: Anti-inflammatory agents, Cardiovascular, Chemical vapor deposition, Clinical, Diabetes, Inflammation, Oxidations, Pharmaceutical, Transcription
Since cholesterol is a water-insoluble molecule it must be packaged for transport within the plasma. The particles that package cholesterol, cholesteryl esters, and triglycerides for transport, are c...
BioFiles 2007, 2.7, 13.
Keywords: Esterifications, Ligands
Peroxisome proliferator activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid and thyroid...
Keywords: Anti-inflammatory agents, Atomic absorption spectroscopy, Cancer, Cell proliferation, Clinical, Diabetes, Diseases, Gene expression, Hormones, Inflammation, Ligands, Lipid Metabolism, Metabolic Pathways, Metabolism, Metabolites, Obesity, Oxidations, RNA immunoprecipitation, Transcription
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Huang XS, Zhao SP, Bai L, et al. Br. J. Pharmacol. 158(3), 706-12, (2009)
Significance and suppression of redundant IL17 responses in acute allograft rejection by bioinformatics based drug repositioning of fenofibrate. Roedder S, Kimura N, Okamura H, et al. PLoS ONE 8(2), e56657, (2013)
Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP. Zhao H, Zhu C, Qin C, et al. Biochem. Biophys. Res. Commun. 432(2), 320-5, (2013)
Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Chan SM, Sun RQ, Zeng XY, et al. Diabetes 62(6), 2095-105, (2013)
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells. Glineur C, Gross B, Neve B, et al. Arterioscler. Thromb. Vasc. Biol. 33(3), 621-8, (2013)
Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart. Babbar L, Mahadevan N, and Balakumar P Naunyn Schmiedebergs Arch. Pharmacol. 386(4), 319-29, (2013)
Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Geng Q, Ren J, Chen H, et al. Clin. Exp. Pharmacol. Physiol. 40(3), 219-26, (2013)
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. Roth EM, Rosenson RS, Jones PH, et al. J. Clin. Lipidol. 6(6), 534-44, (2012)
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Abcouwer SF Diabetes 62(1), 36-8, (2013)
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. Vazzana N, Ganci A, Cefalù AB, et al. J. Am. Heart Assoc. 2(2), e000063, (2013)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?